Login:
 
Practitioner 2011; 255 (1739): 10

5-α reductase inhibitors may delay the progression of low-grade prostate cancer

20 Apr 2011Pais-up subscribers

Giving 5-alpha reductase inhibitors (5-ARIs) to men with low-risk prostate cancer undergoing active surveillance was associated with a lower rate of pathologic progression in a small retrospective cohort study.

Paid-up subscribersThis article can be accessed only if you are a paid-up subscriber to The Practitioner.

To view current online and print subscription rates, and to contact the subscription department, click Subscribe today .